• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IDT
Click for more information
4.76% 10.0¢

IDT AUSTRALIA LIMITED - Announcements

Market Cap $51.58M  ! watchlist Created with Sketch. Add to my watchlist

IDT Australia Limited is a pharmaceutical manufacturing company. The Company is engaged... IDT Australia Limited is a pharmaceutical manufacturing company. The Company is engaged in the supply of products and provision of research and development and other technical services within the pharmaceutical and allied industries. Its business includes research and development, active pharmaceutical ingredient (API) and finished dosage form manufacture (FDF), clinical and commercial, project management, chemical services, analytical chemistry, pharmacy services, pharmaceutical development in all dosage forms, clinical packaging and regulatory affairs services. Its Current Good Manufacturing Practice (cGMP) manufacturing facilities produces both API and FDF across the medicinal cannabis manufacturing space. It also provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms. Its analytical laboratories offer medicinal cannabis cGMP testing.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
IDT Appendix 4D - Half Year ReportPRICE SENSITIVE19/02/19
IDT Investor Presentation to AGMPRICE SENSITIVE22/10/18
IDT On-Market Share Buy-back and Small Parcel Buy-backPRICE SENSITIVE26/09/18
IDT Preliminary Final ReportPRICE SENSITIVE21/08/18
IDT IDT and Cann Group Medicinal Cannabis PartnershipPRICE SENSITIVE07/08/18
IDT Appointment of Chief Executive OfficerPRICE SENSITIVE02/07/18 download Created with Sketch. 317.62KB
IDT Update - Response to FDA Warning LetterPRICE SENSITIVE08/06/18 download Created with Sketch. 119.02KB
IDT IDT receives FDA Warning LetterPRICE SENSITIVE29/05/18 download Created with Sketch. 104.18KB
IDT Divestment of Selected Generic Product PortfolioPRICE SENSITIVE04/04/18
IDT Replacement Appendix 4DPRICE SENSITIVE26/02/18
IDT Strategic and Operational Review UpdatePRICE SENSITIVE26/02/18
IDT Half Yearly Report and AccountsPRICE SENSITIVE26/02/18
IDT Appointment interim Chief Executive OfficerPRICE SENSITIVE16/02/18
IDT IDT Executes API Development AgreementPRICE SENSITIVE09/11/17
IDT CMAX transaction completedPRICE SENSITIVE23/08/17
IDT Appendix 4EPRICE SENSITIVE23/08/17
IDT Resignation of Managing DirectorPRICE SENSITIVE14/07/17
IDT Director Retirement - Graeme BlackmanPRICE SENSITIVE13/06/17
IDT US launch of PindololPRICE SENSITIVE09/05/17
IDT FDA review clears Pindolol for US launchPRICE SENSITIVE27/04/17
IDT Generics Sales UpdatePRICE SENSITIVE12/04/17
IDT Appendix 4DPRICE SENSITIVE21/02/17
IDT Completion of Initial CMAX TransactionPRICE SENSITIVE15/12/16
IDT Mayne Pharma Announces U.S. Launch of IDT's TemozolomidePRICE SENSITIVE22/11/16
IDT 1st generic proprietary product shipped to US, temozolomide,MYX-IDT.AX PRICE SENSITIVE02/11/16
IDT IDT Divests CMAX Clinical Trial Business to I'rom Group-IDT.AX PRICE SENSITIVE28/10/16
IDT Trading halt-IDT.AX PRICE SENSITIVE26/10/16
IDT Awarded Future Industries Manufacturing Program Grant-IDT.AX PRICE SENSITIVE06/09/16
IDT Appendix 4E-IDT.AX PRICE SENSITIVE24/08/16
IDT Completion of private placement-IDT.AX PRICE SENSITIVE30/06/16
IDT Trading Halt-IDT.AX PRICE SENSITIVE28/06/16
IDT CMAX - Opening of new Clinical Trial Facility-IDT.AX PRICE SENSITIVE02/05/16
IDT FDA Approval for Temozolomide-IDT.AX PRICE SENSITIVE13/04/16
IDT Manufacturing partner appointedPRICE SENSITIVE30/03/16
IDT Thiotepa - Contract Extension and RevenuesPRICE SENSITIVE09/03/16
IDT Appendix 4DPRICE SENSITIVE19/02/16
IDT $6m Placement to Accelerate IDT's Generic Drug PortfolioPRICE SENSITIVE19/11/15
IDT Trading HaltPRICE SENSITIVE17/11/15
IDT IDT Executes US Distribution Agreement for TemozolomidePRICE SENSITIVE24/09/15
IDT Appendix 4EPRICE SENSITIVE18/08/15
IDT Appointment US Distributor for Generic PortfolioPRICE SENSITIVE12/08/15
IDT Update-Generic product acquisition and integrationPRICE SENSITIVE13/04/15
IDT Half Year AccountsPRICE SENSITIVE17/02/15
IDT Acquisition 23 US Generic Drugs completedPRICE SENSITIVE18/12/14
IDT Reinstatement to Official QuotationPRICE SENSITIVE03/11/14
IDT IDT to Acquire 23 US Generic Drug ProductsPRICE SENSITIVE03/11/14
IDT Suspension from Official QuotationPRICE SENSITIVE30/10/14
IDT Trading HaltPRICE SENSITIVE28/10/14
IDT Preliminary Final ReportPRICE SENSITIVE20/08/14
IDT US product distributionPRICE SENSITIVE29/07/14
IDTAppendix 4DPRICE SENSITIVE20/02/14
IDTIDT secures Option to acquire HRT Product FilingPRICE SENSITIVE28/01/14
IDTIDT files ANDA for Temozolomide in the USPRICE SENSITIVE18/11/13
IDTRights Issue Offer BookletPRICE SENSITIVE30/08/13
IDTPreliminary Final ReportPRICE SENSITIVE29/08/13
IDTNon renounceable Rights Issue & PlacementPRICE SENSITIVE29/08/13
IDTTrading HaltPRICE SENSITIVE27/08/13
IDTBusiness UpdatePRICE SENSITIVE09/07/13
IDT +Progress on Linguet Ibuprofen formulationPRICE SENSITIVE02/07/13
IDTStrategic PlacementPRICE SENSITIVE07/05/13
IDTBusiness UpdatePRICE SENSITIVE16/04/13
IDTHalf Yearly Report and AccountsPRICE SENSITIVE26/02/13
IDTManaging Director's resignationPRICE SENSITIVE14/12/12
IDTPreliminary Final ReportPRICE SENSITIVE23/08/12
IDTBusiness UpdatePRICE SENSITIVE17/05/12
IDTProfit GuidancePRICE SENSITIVE01/05/12
IDTHalf Yearly Report and AccountsPRICE SENSITIVE17/02/12
IDTProfit updatePRICE SENSITIVE04/10/11
IDTPreliminary Final ReportPRICE SENSITIVE17/08/11
IDTIDT secures government grant for innovative anti cancer drugPRICE SENSITIVE19/07/11
IDTMarket UpdatePRICE SENSITIVE27/04/11
IDTAppendix 4D Half Year ReportPRICE SENSITIVE22/02/11
IDTPreliminary Final ReportPRICE SENSITIVE23/08/10
IDTRevised Prospectus Timetable and Appendix 3BPRICE SENSITIVE14/04/10
IDTBonus Option Offer ProspectusPRICE SENSITIVE14/04/10
IDTPFIZER ASSETS TRANSFERRED AND EARNINGS GUIDANCEPRICE SENSITIVE12/04/10
IDTResponse to a ASX Price QueryPRICE SENSITIVE06/04/10
IDTHalf Yearly Report and AccountsPRICE SENSITIVE16/02/10
IDTPreliminary Final ReportPRICE SENSITIVE18/08/09
IDTHalf Yearly Report and AccountsPRICE SENSITIVE17/02/09
IDTMarket UpdatePRICE SENSITIVE23/12/08
IDT Appendix 4D - Half Year Report
19/02/19PRICE SENSITIVE
IDT Investor Presentation to AGM
22/10/18PRICE SENSITIVE
IDT On-Market Share Buy-back and Small Parcel Buy-back
26/09/18PRICE SENSITIVE
IDT Preliminary Final Report
21/08/18PRICE SENSITIVE
IDT IDT and Cann Group Medicinal Cannabis Partnership
07/08/18PRICE SENSITIVE
IDT Appointment of Chief Executive Officer
02/07/18PRICE SENSITIVE download Created with Sketch. 317.62KB
IDT Update - Response to FDA Warning Letter
08/06/18PRICE SENSITIVE download Created with Sketch. 119.02KB
IDT IDT receives FDA Warning Letter
29/05/18PRICE SENSITIVE download Created with Sketch. 104.18KB
IDT Divestment of Selected Generic Product Portfolio
04/04/18PRICE SENSITIVE
IDT Replacement Appendix 4D
26/02/18PRICE SENSITIVE
IDT Strategic and Operational Review Update
26/02/18PRICE SENSITIVE
IDT Half Yearly Report and Accounts
26/02/18PRICE SENSITIVE
IDT Appointment interim Chief Executive Officer
16/02/18PRICE SENSITIVE
IDT IDT Executes API Development Agreement
09/11/17PRICE SENSITIVE
IDT CMAX transaction completed
23/08/17PRICE SENSITIVE
IDT Appendix 4E
23/08/17PRICE SENSITIVE
IDT Resignation of Managing Director
14/07/17PRICE SENSITIVE
IDT Director Retirement - Graeme Blackman
13/06/17PRICE SENSITIVE
IDT US launch of Pindolol
09/05/17PRICE SENSITIVE
IDT FDA review clears Pindolol for US launch
27/04/17PRICE SENSITIVE
IDT Generics Sales Update
12/04/17PRICE SENSITIVE
IDT Appendix 4D
21/02/17PRICE SENSITIVE
IDT Completion of Initial CMAX Transaction
15/12/16PRICE SENSITIVE
IDT Mayne Pharma Announces U.S. Launch of IDT's Temozolomide
22/11/16PRICE SENSITIVE
IDT 1st generic proprietary product shipped to US, temozolomide,MYX-IDT.AX
02/11/16PRICE SENSITIVE
IDT IDT Divests CMAX Clinical Trial Business to I'rom Group-IDT.AX
28/10/16PRICE SENSITIVE
IDT Trading halt-IDT.AX
26/10/16PRICE SENSITIVE
IDT Awarded Future Industries Manufacturing Program Grant-IDT.AX
06/09/16PRICE SENSITIVE
IDT Appendix 4E-IDT.AX
24/08/16PRICE SENSITIVE
IDT Completion of private placement-IDT.AX
30/06/16PRICE SENSITIVE
IDT Trading Halt-IDT.AX
28/06/16PRICE SENSITIVE
IDT CMAX - Opening of new Clinical Trial Facility-IDT.AX
02/05/16PRICE SENSITIVE
IDT FDA Approval for Temozolomide-IDT.AX
13/04/16PRICE SENSITIVE
IDT Manufacturing partner appointed
30/03/16PRICE SENSITIVE
IDT Thiotepa - Contract Extension and Revenues
09/03/16PRICE SENSITIVE
IDT Appendix 4D
19/02/16PRICE SENSITIVE
IDT $6m Placement to Accelerate IDT's Generic Drug Portfolio
19/11/15PRICE SENSITIVE
IDT Trading Halt
17/11/15PRICE SENSITIVE
IDT IDT Executes US Distribution Agreement for Temozolomide
24/09/15PRICE SENSITIVE
IDT Appendix 4E
18/08/15PRICE SENSITIVE
IDT Appointment US Distributor for Generic Portfolio
12/08/15PRICE SENSITIVE
IDT Update-Generic product acquisition and integration
13/04/15PRICE SENSITIVE
IDT Half Year Accounts
17/02/15PRICE SENSITIVE
IDT Acquisition 23 US Generic Drugs completed
18/12/14PRICE SENSITIVE
IDT Reinstatement to Official Quotation
03/11/14PRICE SENSITIVE
IDT IDT to Acquire 23 US Generic Drug Products
03/11/14PRICE SENSITIVE
IDT Suspension from Official Quotation
30/10/14PRICE SENSITIVE
IDT Trading Halt
28/10/14PRICE SENSITIVE
IDT Preliminary Final Report
20/08/14PRICE SENSITIVE
IDT US product distribution
29/07/14PRICE SENSITIVE
IDTAppendix 4D
20/02/14PRICE SENSITIVE
IDTIDT secures Option to acquire HRT Product Filing
28/01/14PRICE SENSITIVE
IDTIDT files ANDA for Temozolomide in the US
18/11/13PRICE SENSITIVE
IDTRights Issue Offer Booklet
30/08/13PRICE SENSITIVE
IDTPreliminary Final Report
29/08/13PRICE SENSITIVE
IDTNon renounceable Rights Issue & Placement
29/08/13PRICE SENSITIVE
IDTTrading Halt
27/08/13PRICE SENSITIVE
IDTBusiness Update
09/07/13PRICE SENSITIVE
IDT +Progress on Linguet Ibuprofen formulation
02/07/13PRICE SENSITIVE
IDTStrategic Placement
07/05/13PRICE SENSITIVE
IDTBusiness Update
16/04/13PRICE SENSITIVE
IDTHalf Yearly Report and Accounts
26/02/13PRICE SENSITIVE
IDTManaging Director's resignation
14/12/12PRICE SENSITIVE
IDTPreliminary Final Report
23/08/12PRICE SENSITIVE
IDTBusiness Update
17/05/12PRICE SENSITIVE
IDTProfit Guidance
01/05/12PRICE SENSITIVE
IDTHalf Yearly Report and Accounts
17/02/12PRICE SENSITIVE
IDTProfit update
04/10/11PRICE SENSITIVE
IDTPreliminary Final Report
17/08/11PRICE SENSITIVE
IDTIDT secures government grant for innovative anti cancer drug
19/07/11PRICE SENSITIVE
IDTMarket Update
27/04/11PRICE SENSITIVE
IDTAppendix 4D Half Year Report
22/02/11PRICE SENSITIVE
IDTPreliminary Final Report
23/08/10PRICE SENSITIVE
IDTRevised Prospectus Timetable and Appendix 3B
14/04/10PRICE SENSITIVE
IDTBonus Option Offer Prospectus
14/04/10PRICE SENSITIVE
IDTPFIZER ASSETS TRANSFERRED AND EARNINGS GUIDANCE
12/04/10PRICE SENSITIVE
IDTResponse to a ASX Price Query
06/04/10PRICE SENSITIVE
IDTHalf Yearly Report and Accounts
16/02/10PRICE SENSITIVE
IDTPreliminary Final Report
18/08/09PRICE SENSITIVE
IDTHalf Yearly Report and Accounts
17/02/09PRICE SENSITIVE
IDTMarket Update
23/12/08PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
10.0¢ 		Change
-0.005(4.76%) 		Mkt cap ! $51.58M
Open High Low Value Volume
10.5¢ 10.5¢ 9.9¢ $5.546K 55.41K

Buyers (Bids)

No. Vol. Price($)
3 105019 10.0¢
 

Sellers (Offers)

Price($) Vol. No.
10.5¢ 447447 4
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
Last
10.0¢ 		  Change
-0.005 ( 4.76 %)
Open High Low Volume
10.0¢ 10.0¢ 10.0¢ 14966
Last updated 15.59pm 21/11/2024 ?
IDT (ASX) Chart

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.